Li Meng-Meng, Sang Cai-Hua, Jiang Chen-Xi, Guo Xue-Yuan, Li Song-Nan, Wang Wei, Zhao Xin, Tang Ri-Bo, Long De-Yong, Gao Hai, Dong Jian-Zeng, Du Xin, Ma Chang-Sheng
Cardiology Department, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Pacing Clin Electrophysiol. 2019 Dec;42(12):1566-1572. doi: 10.1111/pace.13819. Epub 2019 Oct 30.
Data on management of maternal arrhythmia among Chinese were limited. Radiofrequency catheter ablation (RFCA) proved to be a reliable treatment choice for sustained tachyarrhythmia but it has rarely been performed during pregnancy due to radiation exposure.
To investigate the incidence of idiopathic sustained maternal arrhythmia and the feasibility of RFCA in the pregnant patients without fluoroscopy.
From January of 2015 to December of 2018, the medical records on pregnancy-related admissions in Beijing Anzhen Hospital (Beijing, China) were retrospectively analyzed. Patients who had sustained tachyarrhythmia episodes without structural heart disease were identified. Catheter ablation was performed in those with drug resistant and severely frequent tachyarrhythmia under the guidance of electroanatomical mapping system and intracardiac echocardiography catheter (ICE), if appropriate.
During the study period, 12 584 consecutive pregnant women were admitted for pregnancy-related reasons, 156 (1.2%) of them were identified as sustained maternal tachyarrhythmia. Twenty-eight patients (age 21-37 years) received catheter ablation because the arrhythmias were drug resistant and severely frequent. The RFCA was successfully performed in all patients with zero fluoroscopy after 72.4 ± 24.7 min. Transseptal puncture was performed in 11 patients under the guidance of ICE. In a median of 37 (interquartile range [IQR]: 34-39) weeks' pregnancy, 28 healthy fetuses were delivered. No cardiac-related adverse event occurred during delivery. During later follow-up, all patients were free of arrhythmia, and all the infants were well developed.
Sustained maternal tachyarrhythmia is not uncommon in the clinical practice. To those with drug resistant and severely frequent arrhythmia, RFCA with zero fluoroscopy could be safely performed with acceptable efficacy.
中国关于孕产妇心律失常管理的数据有限。射频导管消融术(RFCA)被证明是治疗持续性快速心律失常的可靠选择,但由于辐射暴露,在孕期很少进行。
调查特发性持续性孕产妇心律失常的发生率以及在无透视情况下对孕妇进行RFCA的可行性。
回顾性分析2015年1月至2018年12月北京安贞医院(中国北京)与妊娠相关住院患者的病历。确定患有无结构性心脏病的持续性快速心律失常发作的患者。对于药物难治性且快速心律失常严重频繁发作的患者,酌情在电解剖标测系统和心内超声导管(ICE)引导下进行导管消融。
在研究期间,12584例因妊娠相关原因连续入院的孕妇中,156例(1.2%)被确定为持续性孕产妇快速心律失常。28例患者(年龄21 - 37岁)因心律失常药物难治且严重频繁发作而接受导管消融。所有患者均成功进行了RFCA,无透视,手术时间为72.4±24.7分钟。11例患者在ICE引导下进行了房间隔穿刺。在妊娠中位数为37周(四分位间距[IQR]:34 - 39周)时,28例健康胎儿顺利分娩。分娩期间未发生与心脏相关的不良事件。在随后的随访中,所有患者均无心律失常,所有婴儿发育良好。
持续性孕产妇快速心律失常在临床实践中并不少见。对于药物难治且严重频繁发作的心律失常患者,可安全地进行无透视的RFCA,疗效可接受。